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Objectives This study sought to develop a method to adjust for case mix complexity in catheteriza-
tion for congenital heart disease to allow equitable comparisons of adverse event (AE) rates.
Background The C3PO (Congenital Cardiac Catheterization Project on Outcomes) has been prospec-
tively collecting data using a Web-based data entry tool on all catheterization cases at 8 pediatric
institutions since 2007.
Methods A multivariable logistic regression model with high-severity AE outcome was built using a
random sample of 75% of cases in the multicenter cohort; the models were assessed in the remain-
ing 25%. Model discrimination was assessed by the C-statistic and calibration with Hosmer-Leme-
show test. The ﬁnal models were used to calculate standardized AE ratios.
Results Between August 2007 and December 2009, 9,362 cases were recorded at 8 pediatric insti-
tutions of which high-severity events occurred in 454 cases (5%). Assessment of empirical data
yielded 4 independent indicators of hemodynamic vulnerability. Final multivariable models included
procedure type risk category (odds ratios [OR] for category: 2  2.4, 3  4.9, 4  7.6, all p  0.001),
number of hemodynamic indicators (OR for 1 indicator  1.5, 2  1.8, p  0.005 and p  0.001),
and age 1 year (OR: 1.3, p  0.04), C-statistic 0.737, and Hosmer-Lemeshow test p  0.74. Models
performed well in the validation dataset, C-statistic 0.734. Institutional event rates ranged from
1.91% to 7.37% and standardized AE ratios ranged from 0.61 to 1.41.
Conclusions Using CHARM (Catheterization for Congenital Heart Disease Adjustment for Risk
Method) to adjust for case mix complexity should allow comparisons of AE among institutions per-
forming catheterization for congenital heart disease. (J Am Coll Cardiol Intv 2011;4:1037–46)
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1038Until recently, the field of pediatric cardiac catheterization
has lacked standardized nomenclature and definitions for
adverse events (AE). This, in turn, led to different arbitrary
definitions for adverse events being used by different insti-
tutions and inhibited the ability to establish benchmarks or
expected outcomes in this specialty (1–7). Comparisons
between and within institutions were further limited by the
lack of ability to adjust for case mix differences. The C3PO
(Congenital Cardiac Catheterization Project on Outcomes)
was developed and executed to overcome these limitations
in our ability to assess and compare outcomes in the field.
Specifically, we sought to collect data in a uniform manner
on all catheterization procedures performed at multiple
institutions, including patient and procedural characteristics
and the occurrence of AE (8). After 1 year of planning and
development of a Web-based
data entry tool, data collection
commenced in 2007, and has
resulted in the creation of a large
multicenter dataset of congenital
cardiac catheterization cases.
Cardiac catheterization in pedi-
atrics and for adults with congen-
ital heart disease encompasses a
broad range of procedures, some
of which occur infrequently, pre-
cluding assessment of risk for in-
dividual procedure types. Further,
there is variation in the frequency
of different procedures between
centers and practitioners and a
wide variety of adverse out-
comes can occur in different
interventions. To account for
procedural diversity, we devel-
oped procedure type risk cate-
gories using both consensus
and empirical methods (9). Al-
though the procedure type risk
ategories have a strong relationship with AEs, other
atient and/or procedural factors may also influence
utcome. Thus, we sought to develop a method of case
ix adjustment that would include the most important
atient and procedural determinants of risk for clinically
mportant AE in a multivariable model. The population
nalyzed included the entire cohort of patients undergo-
ng catheterization for congenital heart disease, with a
econdary cohort consisting of children 18 years of age.
his was necessary to develop a risk adjustment method
ocused on pediatrics in parallel with the broader goal of
eveloping a method for practitioners and institutions
aring for both children and adults with congenital heart
Abbreviations
and Acronyms
AE  adverse event(s)
CI  confidence interval
EDP  end-diastolic pressure
MPAmp  main pulmonary
artery mean pressure
MPAsp  main pulmonary
artery systolic pressure
MVsat  mixed venous
saturation
nonSV  2-ventricle
physiology
OR  odds ratio
RV  right ventricle
SAER  standardized
adverse event ratio(s)
SAsat  systemic arterial
saturation
SV  single-ventricle
physiologyisease.Methods
Data source. After institutional review board approval was
btained, 6 participating centers collected patient and pro-
edural information and the occurrence of adverse events on
ll diagnostic and interventional catheterization procedures
tarting in February 2007. One of the 6 institutions did not
tart collecting data on biopsy cases until March 2009. Two
dditional sites became participants in April 2008 and June
009, respectively. Thus, 8 sites contributed data to the
egistry (Online Appendix). Primary electrophysiology cases
ere not included. This analysis is limited to cases entered
fter August 1, 2007, because additional hemodynamic
ariables were added to the database and prospectively
ollected only after this date.
The methods for data collection and validation were
reviously published (8,9). Patient and procedural charac-
eristics as well as the occurrence and type of adverse events
ere prospectively recorded. The following patient and
rocedural characteristics were recorded: type of case (diag-
ostic, interventional, or biopsy), center, admission status
elective, nonelective, emergent), age, sex, diagnosis, non-
ardiac problem, known or suspected genetic abnormality,
irway management during catheterization (spontaneous
espiration or mechanical support), types of interventions,
ase duration, and hemodynamic variables.
Because cardiac catheterization for congenital heart dis-
ase encompasses such a broad range of therapeutic and
iagnostic procedures, we previously developed procedure
ype risk categories (Table 1). These categories were devel-
ped using both consensus and empirical methods. The
ategories represent procedure types with similar risk of
dverse outcomes during cardiac catheterization procedures
or congenital heart disease (9). As previously described,
ases with multiple procedures were assigned to the category
orresponding to the highest risk procedure.
AE were defined as any anticipated or unanticipated event
rom which injury could have occurred or did occur, potentially
r definitely because of performing the catheterization. Events
ere recorded at the time of identification, either at the time of
he case or later if determined to be related to the procedure.
e used previously established and tested definitions for AE
everity ranging from levels 1 to 5 (Table 2) (1,8). For this
nalysis, clinically important higher severity AE were defined
s levels 3 and 4, or 5 AE. All AE were reviewed for proper
pplication of seriousness definitions by the principal investi-
ator and a designee. Any misapplication of definitions was
eported to the participant and disagreements were resolved.
Hemodynamic vulnerability. It was our supposition that a
patient with abnormal hemodynamics would be at increased
risk for clinically important AE. In previous work at The
Children’s Hospital in Boston, we defined abnormal hemody-
namics using judgment and consensus and were able to show
an association with AE (1). However, the thresholds were
ular sep
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1 Bergersen et al.
S E P T E M B E R 2 0 1 1 : 1 0 3 7 – 4 6 Congenital Catheterization Risk Adjustment
1039arbitrarily defined and not based on data. In this study, we
sought to use empirical data to develop a single composite
indicator of hemodynamic vulnerability based on the hemody-
namic factors with the greatest ability to predict high-severity
AE, while eliminating collinear variables with less explanatory
value. The following 8 hemodynamic variables were assessed
Table 1. Procedure Type Risk Categories
Risk Category 1 Risk Category 2
Diagnostic case Age 1 yr Age 1 month 1 yr
Valvuloplasty Pulmonary valve 1 month
Device or coil
closure
Venous collateral
LSVC
PDA
ASD or PFO
Fontan fenestration
Systemic to pulmonary artery collaterals
Balloon
angioplasty
RVOT
Aorta dilation 8 atm
Stent placement Systemic vein
Stent redilation RVOT
Atrial septum
Aorta
Systemic artery (not aorta)
Systemic vein
Other Myocardial biopsy Snare foreign body
Transseptal puncture
ASD atrial septal defect; CB cutting balloon; LSVC left superior vena cava; PDA patent du
ventricle to pulmonary artery conduit or status post-RVOT surgery with no conduit); VSD ventric
Table 2. Definitions for Adverse Event Severity
Severity Level Definition
1–None No harm, no change in condition, may have required monitoring
for potential change in condition with no intervention indicat
2–Minor Transient change in condition, not life-threatening, condition ret
baseline, required monitoring, required minor intervention su
holding a medication, or obtaining laboratory test.
3–Moderate Transient change in condition may be life-threatening if not trea
condition returns to baseline, required monitoring, required
intervention such as reversal agent, additional medication, tra
the intensive care unit for monitoring, or moderate transcath
intervention to correct condition.
4–Major Change in condition, life-threatening if not treated, change in co
may be permanent, may have required an intensive care unit
or emergent readmit to hospital, may have required invasive
monitoring, required interventions such as electrical cardiove
unanticipated intubation or required major invasive procedur
transcatheter interventions to correct condition.
5–Catastrophic Any death, and emergent surgery or heart lung bypass support
prevent death with failure to wean from bypass support.for inclusion in this composite measure: cardiac index, right
ventricular (RV) systolic pressure, RV to systemic pressure ratio
(RV ratio), systemic ventricle end-diastolic pressure (EDP), mixed
venous saturation (MVsat), systemic arterial saturation (SAsat),
main pulmonary artery systolic pressure (MPAsp), and main
pulmonary artery mean pressure (MPAmp).
Risk Category 3 Risk Category 4
e 1 month
rtic valve 1 month
lmonary valve 1 month
cuspid valve
Mitral valve
Aortic valve 1 month
temic surgical shunt
ﬂe leak
ronary ﬁstula
VSD
Perivalvular leak
lmonary artery 4 vessels
lmonary artery 4 vessels all 8 atm
rta 8 atm or CB
temic artery (not aorta)
temic surgical shunt
temic to pulmonary collaterals
temic vein
Pulmonary artery 4 vessels
Pulmonary vein
OT
rta
temic artery (not aorta)
Ventricular septum
Pulmonary artery
Pulmonary vein
Systemic surgical shunt
Systemic pulmonary collateral
lmonary artery
lmonary vein
Ventricular septum
ial septostomy
analization of jailed vessel in stent
analization of occluded vessel
Atrial septum dilation and stent
Any catheterization 4 days after surgery
Atretic valve perforation
eriosus; PFO patent foramen ovale; RVOT right ventricular outflow tract (RVOT includes right
tal defect.
Examples
sess Balloon rupture
Equipment problem
Groin hematoma
Self-resolving arrhythmia
o
Unstable arrhythmia with preserved blood pressure requiring intervention
Vascular damage not life-threatening but requiring intervention
n
sion
r
Event requiring cardiopulmonary resuscitation
Event leading to surgery or repeat catheterization
Stroke
) to Event resulting in deathAg
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1040Statistical methods. Frequency with percentage or median
with interquartile range (25th and 75th percentiles) were
calculated for patient and procedural characteristics of the
entire cohort and for the subgroup of patients18 years of age.
sing a random sample of 75% of the cases collected between
ugust 1, 2007, and December 31, 2009, the composite
ndicator of hemodynamic vulnerability was derived and mul-
ivariable models for predicting the outcome of high severity
E were developed. Model performance was then assessed
oth in this dataset as well as in the remaining 25% of cases.
HEMODYNAMIC VULNERABILITY INDICATOR. Before any
analyses were conducted, correlations among the 8 hemody-
namic variables were explored using Pearson and Spearman
correlation coefficients. For each individual variable, a receiver-
operator characteristic curve was used to identify the threshold
value that maximized discrimination for predicting a high-
severity AE. A binary variable was then created based on this
cutpoint. The entire cohort was used to derive single threshold
values for cardiac index and EDP. For other variables, such as
MVsat, SAsat, and MPAmp the cohort was divided into
patients with single-ventricle (SV) and 2-ventricle (nonSV)
physiologies. Threshold values for RV, RV ratio, and MPAsp
were only assessed in the nonSV subset of the cohort.
Once the best threshold value had been determined for
each of the 8 individual hemodynamic variables, the result-
ing binary variables were used to create a composite hemo-
dynamic vulnerability indicator. Multivariable logistic re-
gression with backward elimination was used to identify the
subgroup of hemodynamic variables with the greatest ability
to predict a high-severity AE. We started with a model
containing all 8 hemodynamic variables, and removed them
1 at a time. If the area under the receiver-operator charac-
teristic curve improved when a variable was removed, that
variable was eliminated and the process repeated until
eliminating an additional variable no longer improved the
discrimination of the model. Once the most important
hemodynamic variables were identified, we considered dif-
ferent methods of combining them to quantify hemody-
namic vulnerability. This included using each hemodynamic
risk factor as a simple binary variable indicating whether a
case had any of the hemodynamic risk factors, taking the
total number of hemodynamic risk factors present, and
combining the number of risk factors into a score. Factors
were weighted according to whether they were more or less
predictive of the outcome. The simplest model with the
highest discrimination was chosen as the final composite
indicator of hemodynamic vulnerability.
RISK ADJUSTMENT MODEL. The random sample of 75% of
he cases collected between August 1, 2007, and December
1, 2009, was used to create a multivariable logistic regres-
ion model for the outcome severity levels 3 and 4, or 5 AE
n the entire cohort, as well as in the secondary cohort of
hildren 18 years of age. Forward selection was used. The
atient characteristic with the highest statistically significant tmprovement in the area under the receiver-operator char-
cteristic curve (C-statistic), as assessed by the likelihood-
atio test, was retained in the model, and the remaining
ariables were reassessed. This process was repeated until
here was no significant contribution to outcome prediction
or any of the remaining variables.
The following patient and procedural characteristics were
onsidered to develop the model: procedure risk category,
iagnosis, age, noncardiac problem, known or suspected
enetic abnormality, and hemodynamic vulnerability. Odds
atio (OR) with 95% confidence intervals (CIs) are pre-
ented for the final risk adjustment models. The Hosmer-
emeshow goodness of fit test was used to assess calibration
10,11). Discrimination and calibration were also assessed in
he validation datasets.
CHARM. The final CHARM (Catheterization for Congen-
ital Heart Disease Adjustment for Risk Method) model was
used to determine risk-adjusted AE rates for severity levels
3 and 4, or 5 AE by institution for the entire cohort as well
as for children18 years of age. Standardized adverse event
ratios (SAER) were calculated by dividing the observed AE
rate within each institution by the expected AE rate
accounting for the institution’s case mix. To calculate the
expected AE rate, the expected number of events was
counted for each institution by summing the predicted
probabilities of the outcome—generated from the final
logistic regression model—for each case within that institu-
tion. The expected number of events was then divided by the
total number of cases at that institution to calculate the
expected rate. A SAER of 1.0 indicates that the observed event
rate is equal to the expected rate given the institution’s case mix
complexity. If the SAER is 1.0, the institution has more
events than would have been expected. If the SAER is 1.0,
he institution has fewer events than expected. The 95% CIs
ere calculated for each SAER; if a CI does not contain the
alue 1.0, then the AE rate for that institution is significantly
ifferent from average (p  0.05).
Results
Population. Between August 1, 2007, and December 31,
009, 9,362 diagnostic and interventional cardiac catheter-
zation cases were recorded in the database, 85% of which
ere performed in children 18 years of age (Table 3).
ne-half the population was composed of patients with SV
irculation or complex 2-ventricle anatomy with outflow
ract obstruction and/or intracardiac shunts due to septal
efects. Twenty percent of the population had isolated
esions such as an atrial septal defect, patent ductus arteri-
sus, or valve abnormality. Genetic abnormalities were
resent in 12% of the cohort and noncardiac problems in
7%. Most of the procedures were performed electively
81%). When the population was limited to pediatric patients,
here was a lower prevalence of spontaneous respirations as the
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1041method of airway management (25% vs. 31%). Patient and
procedural characteristics were otherwise similar. The lowest
procedure type risk category comprised the largest proportion
of the procedures, with 42% in category 1, 29% in category 2,
19% in category 3, and 10% in category 4. The outcome for the
Table 3. Patient and Procedural Characteristics August 1, 2007,
to December 31, 2009
Entire Cohort
(N  9,362)
<18 Years of Age
(n  7,970)
Patient characteristics
Age
1 month 637 (7) 637 (8)
1–11 months 1,699 (18) 1,699 (21)
1–9 yrs 3,598 (38) 3,598 (45)
10 yrs 3,425 (37) 2,036 (26)
Male 4,909 (52) 4,224 (53)
Diagnosis
No structural heart disease* 2,571 (27) 2,114 (27)
Pulmonary hypertension 262 (3) 220 (3)
Isolated defects 1,933 (21) 1,612 (20)
Complex defect with 2 ventricles 2,847 (30) 2,402 (30)
Complex defect with 1 ventricle 1,746 (19) 1,621 (20)
Genetic syndrome 1,091 (12) 996 (13)
Noncardiac problem 2,475 (27) 1,975 (25)
Procedural characteristics
Case type
Diagnostic 2,561 (27) 2,127 (27)
Interventional 4,589 (49) 4,037 (51)
Biopsy 2,212 (24) 1,806 (23)
Admission type
Elective 7,537 (81) 6,261 (79)
Nonelective 1,661 (18) 1,553 (19)
Emergent 162 (2) 154 (2)
Spontaneous respirations 2,864 (31) 2,024 (25)
Types of interventions
Any balloon angioplasty 1,480 (16) 1,339 (17)
Any valvotomy 590 (6) 557 (7)
Any stent placement 1,275 (14) 1,073 (13)
Any device placement 1,298 (14) 1,065 (13)
Any coil placement 850 (9) 811 (10)
Procedure type risk categories
Category 1 3,934 (42) 3,092 (39)
Category 2 2,698 (29) 2,402 (30)
Category 3 1,751 (19) 1,582 (20)
Category 4 979 (10) 894 (11)
Case duration
1 h 3,362 (36) 2,830 (36)
1 h, 2 h 3,860 (41) 3,345 (42)
2 h, 3 h 1,469 (16) 1,252 (16)
3 h 652 (7) 527 (7)
Any level 3, 4, or 5 severity AE 454 (5) 407 (5)
Values are n (%). *Examples include patients with cardiomyopathy or after heart transplantation.
AE adverse events.risk adjustment model, high-severity AE, occurred in 5% ofthe entire cohort and at a similar rate in the secondary cohort
of patients 18 years of age.
Hemodynamic vulnerability. The following correlations
ere found among the hemodynamic variables: 1) higher
ardiac index and higher MVsat; 2) higher MVsat, higher
Asat, and lower RV ratio; and 3) higher RV ratio, higher RV,
igher MPAsp, and MPAmp. None of the other hemody-
amic variables were associated with EDP (Fig. 1). We
ssigned threshold values empirically for each of the 8
emodynamic variables (Table 4, Fig. 2). Multivariable
odeling yielded 4 indicators of hemodynamic vulnerability
ndependently associated with the occurrence of a high
everity AE: EDP 18 mm Hg; SAsat 95% if nonSV or
78% if SV; MVsat 60% if nonSV or 50% if SV; and
PAsp 45 mm Hg if nonSV or MPAmp 17 mm Hg if
V. The number of hemodynamic variables present among
hese 4 categorized as 0, 1, 2, or more was the simplest
omposite indicator of hemodynamic vulnerability for pre-
icting the outcome any severity levels 3 and 4, or 5 AE
C-statistic: 0.632) (Table 5).
Multivariable risk adjustment model: CHARM. The final
multivariable model for the overall cohort included proce-
dure type risk category, number of hemodynamic indicators,
and age 1 year, with a C-statistic of 0.737 and Hosmer-
Lemeshow test p value 0.74 (Table 6). For the age variable,
we started with 5 categories (age1 month, 1 month to1
year, 1 to 10 years, 11 to 17 years, 18 years) but then
collapsed categories with OR that were not significantly
different from each other. In the secondary cohort of
patients 18 years of age, the same 3 variables were
identified; the model showed similar predictive performance
and calibration, C-statistic: 0.734, and Hosmer-Lemeshow
Figure 1. Correlations Among Hemodynamic Variables
The hemodynamic variables assessed were found to be correlated as
depicted in the bubble diagram. Higher cardiac index (CI) was related to
higher mixed venous saturation (MVsat). Higher MVsat was also related
to higher systemic arterial saturation (SAsat) and lower right ventricular to
systemic pressure ratio (RV ratio). Higher RV, pulmonary artery (MPA), and
RV ratio were correlated. Differences in end-diastolic pressure (EDP) in the
systemic ventricle were not related to the other hemodynamic variables
assessed.
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1042test p  0.52. Models also performed well in the validation
dataset, C-statistic: 0.734 for the entire cohort (Hosmer-
Lemeshow p  0.20) and 0.728 (Hosmer-Lemeshow p 
.10) when limited to patients 18 years of age.
The observed adverse event rates among the 8 institutions
anged from 1.91% to 7.37% for the entire cohort (Table 7).
imilarly, for patients 18 years of age, there was a wide
ange of observed AE rates among institutions, 1.71% to
.86%. The CHARM model was used to determine an
xpected AE rate based on the case mix for each of the
nstitutions, and SAERs were determined. For all institu-
ions, SAER ranged from 0.61 to 1.41 in the entire cohort
nd 0.51 to 1.39 in patients 18 years of age (Fig. 3).
nstitutions C and G had lower AE rates than would be
xpected given their case mix, whereas institution E had a
igher rate than would be expected.
iscussion
The C3PO collaborative group has been accruing data on all
congenital catheterizations at several U.S. centers over the
course of more than 3 years, with data from nearly 10,000 cases
available for this analysis. The investigative group previously
was able to stratify catheterization procedure types based upon
the risk for adverse outcomes, initially using expert consensus,
then modifying the procedure type categories based on empir-
ical methods (9). The risk categories were validated through
comparison to a separate cohort of prospectively collected
patients. In this analysis, we have identified 4 important
hemodynamic variables associated with adverse outcomes in-
cluding: systemic ventricular EDP 18 mm Hg, a SAsat
95% (or 78% if SV), MVsat 60% (or 50% if SV), and
ulmonary artery systolic pressure45 mm Hg (or mean17
f SV). These easily and commonly measured factors of
emodynamic vulnerability, when combined with the previ-
usly validated procedure type risk categories and patient age,
an be applied to make comparisons of the outcome of
igh-severity AE by adjusting for some of the case mix
Table 4. Potential Indicators of Hemodynamic Vulnerability and Empirically
Sample Size, N Cutpoint P
Cardiac index 6,160 2.8
Systemic ventricle EDP 4,909 18
MVsat 6,619 60 nonSV 50 SV
SAsat 6,322 95 nonSV 78 SV
MPAmp 6,214 26 nonSV 17 SV
MPAsp 6,501 45 nonSV
Systolic RV 6,546 45 nonSV
RV ratio 4,923 0.4 nonSV
AE  adverse event; CI  confidence interval; EDP  end-diastolic pressure; MPAmp  main pulm
saturation; nonSV 2-ventricle physiology; ROC receiver-operator characteristic; RV right venifferences at different centers.Risk adjustment. Risk adjustment has been successfully
employed for many years in the fields of adult cardiology
coronary intervention and pediatric cardiac surgery (12–14).
This is a much more difficult process in pediatric cardiology,
given the wide heterogeneity of diagnoses and types of
interventions, as well as the relatively limited sample size of
patients as a whole. However, despite this heterogeneity,
risk adjustment models, including the RACHS-1 (Risk
Adjustment in Congenital Heart Surgery) score and the
Aristotle system, have been developed and have been included
in the Society of Thoracic Surgeons and European Association
for Cardio-Thoracic Surgery databases for congenital cardiac
surgery for many years; the data have been useful in improving
the ability to compare institutional outcomes adjusted for case
mix and certain patient variables (15–20).
There is a comparative deficit in outcomes assessment in
the realm of pediatric interventional cardiology, which has
lagged behind in the development of a broadly collected,
inclusive, and prospective database with sufficient anatomic
and physiological information to allow for substantive in-
terrogation. Currently, there are several groups gathering
this type of data, including C3PO, the MAGIC (Mid-
Atlantic Group of Interventional Cardiology), and the
CCISC (Congenital Cardiovascular Interventional Study
Consortium), but these efforts have been relatively recent
and there is limited ability to cross-communicate between
the systems (8,21–23). There is an effort to make a more
widely used outcomes registry through the American Col-
lege of Cardiology IMPACT (Improving Pediatric Adult
Congenital Treatments) registry, which began in 2011 (24).
Once the data are available, there will be a need for one or
more methods allowing comparison between centers and
interventionalists, given the wide variation in case type,
referral patterns, and approaches to care between these
groups. Physicians are understandably concerned that they
be fairly compared when sensitive topics such as outcomes
and adverse event rates are being critically evaluated and
used for compensation and accreditation. In some states,
ed Threshold Values for the Outcome High Severity AE
s, n (%) Odds Ratio 95% CI p Value Area Under ROC
(19%) 1.5 1.1–1.9 0.009 0.532
(7%) 1.8 1.2–2.6 0.005 0.523
(14%) 2.6 2.0–3.4 0.001 0.576
(29%) 1.9 1.5–2.4 0.001 0.573
(23%) 2.0 1.6–2.6 0.001 0.573
(13%) 2.7 1.9–3.6 0.001 0.618
(28%) 2.7 2.0–3.5 0.001 0.634
(40%) 2.0 1.4–2.8 0.001 0.598
artery mean pressure; MPAsp  main pulmonary artery systolic pressure; MVsat  mixed venous
V single ventricle physiology.Deriv
atient
1,190
355
905
1,827
1,412
854
1,865
1,953
onarythese will also be available in the public record.
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1043Figure 2. ROC Curves for the Final Hemodynamic Variables
Receiver-operator characteristic (ROC) curves were assessed for all the hemodynamic variables to determine threshold values with the most predictive perfor-
mance. In this ﬁgure, the curves for the ﬁnal variables are shown with the threshold value in red. (A) Mixed venous saturation in nonsingle-ventricle physiology
(MVsat nonSV). (B) Mixed venous saturation in single ventricle-physiology (MVsat SV). (C) Systemic arterial saturation in nonsingle-ventricle physiology (SAsat
nonSV). (D) Systemic arterial saturation in single-ventricle physiology (SAsat SV). (E) Pulmonary artery systolic pressure in nonsingle-ventricle physiology (PAsp
nonSV). (F) Pulmonary artery mean pressure in single-ventricle physiology (PAmp SV). (G) Systemic ventricle end-diastolic pressure (EDP).
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1044The hope is that interventionalists will be able to use these
data to improve patient care and outcomes, not just to satisfy
outside agencies. For a tool to be useful, it must be able to
collect data in a standardized fashion, with easily understand-
able terminology that will be uniformly employed by the
myriad of physicians and administrators who will ultimately
Table 5. Final Indicator of Hemodynamic Vulnerability for the Outcome
High-Severity AE
AE Rates
Hemodynamic
Sample Size Any 3/4/5 AE (%)
Any 3/4/5 AE
Variables (n of 4)* OR 95% CI p Value
0 4,212 3.0 1.0 — —
1 1669 6.4 2.2 1.7–2.8 0.001
2 1,141 8.8 3.1 2.3–4.0 0.001
*Hemodynamic variables: EDP18 mmHg, SAsat95% if nonSV or78% if SV, MVsat60% if
nonSV or50% if SV, and MPAsp45 mm Hg if nonSV or MPAmp17 mm Hg if SV.
OR odds ratio; SAsat systemic arterial saturation; other abbreviations as in Table 4.
Table 6. Multivariable Models for Risk Adjusting Hig
Outcome: An
All Ages*
Derivatio
OR 95%
Risk category
2 2.4 1.6–3
3 4.9 3.4–7
4 7.6 5.2–1
Hemodynamic variables, n (of 4)
1 1.5 1.1–2
2 1.8 1.3–2
Age 1 yr 1.3 1.1–1
Area under ROC curve 0.737
Hosmer-Lemeshow test p value 0.74
Age <18 yrs*
Risk category
2 2.1 1.4–3
3 4.5 3.0–6
4 7.0 4.6–1
Hemodynamic variables, n (of 4)
1 1.6 1.2–2
2 1.9 1.4–2
Age 1 yr 1.3 1.0–1
Area under ROC curve 0.734
Hosmer-Lemeshow test p value 0.52
Sample calculation of predicted probability of a high-severity AE use
hemodynamic risk factor andage1year, ln[p/1p]4.3588 (0.883
2.8431, and the predicted probability of a high-severity AE is p 0.055
correlation among cases from the same institutionwere similar to thos
risk3 1.5972, risk4 2.0345, hemodynamic1 0.3960, hemodynamic2 0.5
risk2 0.7478, risk3 1.5137, risk4 1.9424, hemodynamic1 0.4409, hemodROC receiver-operator characteristic; other abbreviations as in Tables 3, 4use the system. The data must be stringently acquired and are
likely to be improved by intermittent auditing for completeness
and accuracy. The tool must be generalizable to the entire
population and have demonstrated reliability in multiple set-
tings. Although similar methods were used previously to derive
a risk adjustment method at Children’s Hospital in Boston, it
was always considered preliminary because it was derived using
only a single institutional dataset (25).
Hemodynamic vulnerability indicator. Empirical data in-
ormed the development of the indicator of hemodynamic
ulnerability. Based on our experience, the 4 hemodynamic risk
actors incorporated in the composite indicator variables also
ave significant face validity. However, there are some limita-
ions with the indicator of hemodynamic vulnerability. Because
f nonlinear relationships between hemodynamic values and
isk of AE, we chose to use binary rather than continuous
ariables that meant threshold values were required. Although
ased on data, we admit that the thresholds may not be an
mportant distinction for an individual patient, for example, an
rity AE Rates
l 3/4/5 AE
set Validation Dataset
p Value OR 95% CI p Value
0.001 2.0 1.0–3.8 0.04
0.001 4.9 2.7–9.0 0.001
0.001 4.8 2.5–9.2 0.001
0.005 1.8 1.2–2.8 0.01
0.001 2.0 1.2–3.3 0.008
0.04 1.5 1.0–2.2 0.05
0.734
0.20
0.001 1.7 0.9–3.5 0.12
0.001 4.6 2.4–8.9 0.001
0.001 4.4 2.2–8.9 0.001
0.003 1.9 1.2–3.1 0.007
0.001 1.8 1.0–2.3 0.03
0.05 1.5 1.0–2.3 0.05
0.728
0.10
mputation of expected AE rate: for a patient in risk category 2 with 1
(1.59720) (2.03450) (0.39601) (0.58030) (0.23661)
lts from generalized estimating equation models that account for the
nted.Model coefficients for all ages: intercept –4.3588, risk2 0.8831,
e 0.2366. Model coefficients for age 18 years: intercept –4.3034,
2 0.6434, age 0.2380.h-Seve
y Leve
n Data
CI
.6
.2
1.2
.0
.4
.6
.2
.8
0.6
.1
.6
.7
d in co
11)
. *Resu
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1045EDP of 17 mm Hg versus 18 mm Hg. Also, because they were
empirically derived, different thresholds may have been chosen
in a different dataset. Another limitation pertains to the
measurement of these factors. Limited hemodynamic data may
be obtained in a very ill or otherwise high risk patient resulting
in the inability to account for risk due to lack of measurement.
But by combining multiple variables in our final composite
indicator of vulnerability variable (0, 1, or 2 or more), we
sought to overcome this limitation in most cases.
Institutional variation. It is important to consider the wide
ariation in observed AE rates by institution, ranging from
Figure 3. SAER by Institution
Standardized adverse event ratio (SAER) by institution for the entire cohort (A
conﬁdence interval for each of the 8 participating institutions. SAER were calcu
Table 7. SAER for C3PO Participant Institutions
Institution
Number of
Cases
Observed
Event
Rate
Expected
Event
Rate SAER 95% CI
All ages
A 1356 4.65 4.94 0.94 0.72–1.20
B 3,078 5.88 5.66 1.04 0.89–1.20
C 931 2.58 4.13 0.62 0.40–0.93
D 805 6.58 5.59 1.18 0.88–1.54
E 828 7.37 5.22 1.41 1.08–1.81
F 1,186 3.71 3.96 0.94 0.68–1.26
G 1,048 1.91 3.14 0.61 0.37–0.94
H 130 6.15 4.91 1.25 0.54–2.47
18 yrs of age
A 1,265 4.90 5.04 0.97 0.75–1.25
B 2,533 6.12 6.04 1.01 0.86–1.19
C 839 2.74 4.26 0.64 0.41–0.97
D 636 7.86 6.01 1.31 0.97–1.72
E 778 7.33 5.29 1.39 1.05–1.79
F 947 4.01 4.26 0.94 0.67–1.29
G 879 1.71 3.36 0.51 0.28–0.84
H 93 7.53 5.60 1.34 0.54–2.77
CI  confidence interval; C3PO  Congenital Cardiac Catheterization Project on Outcomes;
SAER standardized adverse event ratio.ming the predicted probabilities of the outcome, generated from the logistic regres.9% to 7.4%, and the narrower range of expected rates (3.1%
o 5.7%) as supporting evidence of the need for a risk
djustment method to make equitable comparisons. Our anal-
sis did show statistically significant variation in SAER at
ifferent institutions, even after risk adjustment, with 1 high
nd 2 low outliers. However, a number of factors potentially
nfluencing the SAER must be considered before interpreta-
ion. First, one must consider the reliability of event reporting
t different institutions, especially those with SAER 1.0. In
he C3PO dataset, an independent record review and moni-
oring of a 10% sample revealed a 91% capture of high-severity
vents (9), but differential reporting remains a possibility.
econd, and perhaps most importantly, we have not made any
djustment or consideration of efficacy as it relates to safety.
re institutions with lower than expected event rates avoiding
aking on risk at the expense of completing all the objectives of
he procedure? This must be considered carefully in the future
s we try to understand what risk we must accept to achieve the
est outcomes (26). Institutional comparisons cannot be re-
arded as definitive unless comparisons of both efficacy and
afety are included. Alternatively, on the other extreme, does
he 1 institution with lower 95% CI of 1.08 represent a
erformance outlier? Perhaps, but there may be unmeasured
actors not accounted for, or optimized, in these models that
re associated with higher event rates, but not associated with
he quality of care. For example, although the models were
eveloped using both pediatric and adult data, there may be
actors unique to the adult congenital population that may be
mportant to consider in a model for an isolated adult popu-
ation, such as comorbidities not as common in the pediatric
opulation. Despite the large size of the cohort used to derive
nd test our models, only 15% of the data was from adults18
ears of age. Finally, there may be differences in physician
erformance such as procedural duration, which was found to
e independently associated with higher event rates in previous
population 18 years of age (B) are shown with bars representing the 95%
by dividing the observed AE rate by the expected rate calculated by sum-) and
latedsion model, for all cases performed at the institution.
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1046work (1). At present, taking into account these issues, we
elieve the CHARM model can be used to make comparisons
f AE rates after pediatric cardiac catheterizations and can be
egarded as a preliminary way to make similar comparisons for
dult congenital heart procedures. As additional data for adult
ongenital procedures accrues, the performance of the
HARM model can be assessed further and refined if
ecessary.
onclusions
The CHARM model to adjust for case mix complexity,
based on procedure type, hemodynamic features, and age
allows for equitable comparisons of adverse event rates
among the institutions performing catheterization for con-
genital heart disease.
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APPENDIX
For a list of the expert panel and participating centers, please see the
online version of this paper.
